Our scientists work with a simple purpose - find the unmet needs in
chronic disease and translate them into new therapeutic solutions. One
of those ideas is advancing type 2 diabetes treatment from injections
This has been a goal for many years, but the challenge has been
the body’s digestive system. Once swallowed, biological medicines,
like insulin, are digested by enzymes in the body, the same way food
is broken down. We needed to find a way for biological medicines to
get through the digestive system intact and get into the blood.
We have recently succeeded and shown that a synthetic version of
the glucagon-like peptide 1 (GLP-1) hormone can be taken in a
tablet. The GLP-1 hormone is naturally produced in the gut and gets
released in response to food. When released, GLP-1 stimulates
insulin production in the pancreas, which again lowers the amount of
glucose in the blood.
This is the world’s first oral treatment for type 2 diabetes with
a GLP-1 receptor agonist. We hope that it will not be too long
before we will be able to offer a broader range of oral treatments.
Not only for diabetes, but for the other serious chronic diseases
in our research portfolio.